Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults
Key facts
- Who runs it
- Korea University Guro Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 180 people, planned
- Started
- 21 Sept 2026
- Expected to end
- Dec 2028
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard dose influenza vaccine
- MF59 adjuvanted influenza vaccine
- High dose influenza vaccine
- Record updated
- 24 September 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Older adult group: aged 65 years or older
- Younger reference group: aged 19 to 49 years
- Able to receive influenza vaccination and complete the scheduled follow up
Who cannot take part
- Receipt of an influenza vaccine or any other vaccine within 4 weeks prior to enrollment
- Immunocompromised status, including ongoing chemotherapy or immunosuppressive therapy, high dose corticosteroid therapy, history of solid organ or hematopoietic stem cell transplantation, active malignancy, HIV infection, or other clinically significant immunocompromising conditions
- Moderate or severe acute infection
- History of allergic reaction to an influenza vaccine or any of its components, or any other condition that precludes influenza vaccination
- Inability, as determined by the investigator, to understand the purpose and procedures of the study and provide voluntary informed consent
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare immune responses to different influenza vaccine formulations in older adults and to understand how immune aging and repeated annual influenza vaccination affect these responses.
Read full original descriptionShow less
The main questions it aims to answer are:
* Do standard dose, MF59 adjuvanted, and high dose influenza vaccines produce different immune responses in adults aged 65 years or older? * How does immune aging affect responses to different influenza vaccine formulations? * How do immune responses change with repeated annual influenza vaccination, and do these changes differ among vaccine formulations?
Researchers will compare older adults who receive a standard dose, MF59 adjuvanted, or high dose influenza vaccine. Younger adults aged 19-49 years who receive a standard dose influenza vaccine will also be included as a reference group to help evaluate age related differences in immune responses.
Participants will:
* Receive an influenza vaccine. * Provide blood samples before and after vaccination to measure antibody and other immune responses. * Some participants will provide additional blood or nasal samples for more detailed evaluation of immune responses.
The 4 groups in the trial
- older adults- standard dose influenza vaccineExisting treatment, for comparison
Treatment: Standard dose influenza vaccine
- older adults- adjuvanted influenza vaccineTreatment being tested
Treatment: MF59 adjuvanted influenza vaccine
- older adults- high dose influenza vaccineTreatment being tested
Treatment: High dose influenza vaccine
- younger adults- standard dose influenza vaccineOther group
Younger adults aged 19-49 years who receive a standard dose influenza vaccine and serve as a reference group for evaluating age related differences in immune responses
Treatment: Standard dose influenza vaccine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Immunogenicity of Different Influenza Vaccine Strategies in Older Adults in a Repeated Vaccination Setting
- Record updated
- 24 September 2026